He describes how Cloverleaf believes it is different from other tRNA companies and how it has already at the earliest stages benefitted...

McKinsey Boston life science specialists give their take on the goals of the summit and the current state of the sector.

He talks about GV's history in healthcare and lists some investments made in the nearly five years he has been there.

Kendalle Burlin O'Connell describes the goals of the Align Summit and the work MassBio is doing.

He discusses Intra-Cellular, Axsome, Adaptimmune, EyePoint, Insmed, Immunocore, Immatics, and Terns.

Eddie Eltoukhy explains the unique role that seed investors have in helping entrepreneurs succeed, he lists some areas of science of...

He discusses Vertex's acquisition of Alpine Immune Science, Bloomberg's reporting on Janux, and more.

Dr. Yu describes how TCGX's structure and nimbleness has led to investments in number companies that have been acquired over the last year.

Dr. Bertozzi and Dr. Hsiao describe how Acepodia is leveraging biorthogonal chemistry to conjugate antibodies to allogeneic γδ2 T cells.

Thomas Shrader shares his thoughts on biotech and comments on companies he covers.

Andy Hsieh gives his take on the radiopharmaceutical space, Viking’s obesity data, Pyxis Oncology, Cardiff Oncology, Fibrogen.

Evan Seigerman breaks down which companies and technologies are at the forefront of the the GLP space.

Ali Gorman will be covering biotech news and cool research in the greater Philadelphia area for BiotechTV.

Matt Phipps covers Janux, NewAmsterdam, Jasper, Autolus, Incyte, Merus, and Amgen.

Laura Chico gives her take on the state of biotech and discusses Denali, Praxis, Viridian, Apellis, PepGen, and Edgewise.

Fabrice Chouraqui describes Cellarity's platform and how it is being put to use for indications such as sickle cell disease and MASH.

CEO Michael Davidson describes how Obicetrapib, which was reacquired from Amgen, is designed to produce more LDL lowering than others.

Jim Porter describes the chemistry that has led to early stage success against ALK and ROS1.

Mark Valleca describes Black Diamond's 'MasterKey' approach to precision oncology that's aimed at solving many mutations at once.

Fred Aslan describes how Artiva is harnessing the ability of NK cells to act as a modulator of antibody dependent cellular cytotoxicity.